<div id="readability-page-1"><div>Kalb Michael Wayne Chief Financial Officer of Catalyst Pharmaceuticals Inc [CPRX] filed a Form 4 on November 24, 2025 with the Securities and Exchange Commission disclosing the following changes in ownership:<div><table><tbody><tr><th>Date</th><th>Transaction</th><th>Shares</th><th>Price</th><th>Value</th></tr><tr><td>11/21/25</td><td>Exercise</td><td>6,894</td><td>$0.00</td><td>N/A</td></tr><tr><td>11/21/25</td><td>Surrender(1)</td><td>2,485</td><td>$23.28</td><td>$57,851</td></tr></tbody></table></div>Ending Holdings: 8,606 - Direct<ul><li>(1)</li><li>Surrender of shares back to company to pay option exercise cost and/or resulting tax liability.</li></ul>For a free trial, or to learn more about our insider trading analysis and data services, please visit http://www.washingtonservice.com or contact us at (301) 913-5100 or send an email to info@washingtonservice.com.Founded in 1970, The Washington Service provides securities professionals with financial, economic and public policy research and data. </div></div>

CPRX

CFO Kalb Acquires 4,409 Of Catalyst Pharmaceuticals Inc [CPRX]